Table 4.
Comparison of pathologies between the NACT-LG and LG groups.
| NACT-LG (n = 41) | LG (n = 35) | P | |
|---|---|---|---|
| Number of resected lymph nodes | 37 (12–91) | 32 (12–69) | 0.081 |
| Number of metastatic lymph nodes | 1 (0–36) | 8 (1–27) | 0.001 |
| pT stage | 0.008 | ||
| 0–2 | 12 (29.3) | 0 (0) | |
| 3–4 | 29 (70.7) | 35 (100.0) | |
| pN stage | < 0.01 | ||
| 0 | 15 (36.6) | 0 (0) | |
| 1–3 | 26 (63.4) | 35 (100.0) | |
| pTNM stage | < 0.01 | ||
| 0–II | 21 (51.2) | 0 (0) | |
| III | 20 (48.8) | 35 (100.0) | |
| Tumor regression grades | NA | ||
| 0 | 4 (9.8) | NA | |
| 1 | 13 (31.7) | NA | |
| 2 | 10 (24.4) | NA | |
| 3 | 14 (34.1) | NA | |
| Pathological complete response | 4 (9.8) | NA | |
Fisher’s exact test was used as an alternative to Chi-square test when the number in one of the cells is smaller than 5.
NACT neoadjuvant chemotherapy, LG laparascopic gastrectomy, NA not applicable.